Alzheimer's Disease
A Cellzome protein localization experiment in primary neurons.
Alzheimer's Disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills. It is the most common cause of dementia in older people.
Disease statistics:
- About 20 million people are affected world-wide and at the current rate the number
is expected to double by 2025. - In the United States alone, more than 4.5 million people are currently afflicted with
the disorder, resulting in healthcare costs of close to $ 100 billion annually. - The AD therapeutic market is currently valued at $ 4.7 billion in the major markets
(US, UK, Germany, France, Italy, Spain and Japan) and is expected to increase to
$ 7.8 billion by the year 2010.
The first symptoms of AD usually set in after the age of 60. With the degeneration of healthy brain tissue, intellectual and social abilities are lost and patients eventually are left with little comprehension or awareness.
Amyloid plaques are the pathological hallmark of Alzheimer's Disease and form as the disease develops in the brains of Alzheimer's patients. At Cellzome, we have mapped the protein interaction network around the disease pathway and identified several target candidates.
« Back